Safety Shot (NASDAQ: SHOT) today announced the west coast launch of Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Safety Shot is a nutraceutical functional beverage, created by industry experts and validated by research, that accelerates the body’s break-down of alcohol while aiding in recovery and rehydration. “Our west coast launch in the Los Angeles area is aligned with our national online direct-to-consumer sales launch through our own website and through Amazon. We are super excited to have people try Safety Shot. We have given out thousands of sample cans and run hundreds of BAC tests already and have proven that trying Safety Shot is believing in Safety Shot,” said Safety Shot CEO Brian John. “Launches in Las Vegas and Phoenix/Scottdale are soon to follow.”
To view the full press release, visit https://ibn.fm/HBzXV
About Safety Shot Inc.
Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Safety Shot will be available for retail purchase in the first week of December 2023 at www.DrinkSafetyShot.com and www.Amazon.com. The company plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars in the first quarter of 2024. Safety Shot plans to spin off legacy assets from its Jupiter Wellness business to unlock value for shareholders.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Quantum BioPharma (NASDAQ: QNTM) announced that it has filed a supplement to its Sept. 28,…
Earth Science Tech (OTCQB: ETST), a diversified holding company operating across healthcare, pharmacy, technology, telemedicine,…
Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…
VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its…
Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical…
This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid…